FIELD: organic chemistry of heterocyclic compounds, medicine, pharmacy. SUBSTANCE: invention relates to novel compounds of the general formula (I): where R is taken among a group including R2, R2NH- or R3R4N-R5- where R2 is taken among a group including C9-C12-alkyl,
and
where each R6 is taken independently among a group including hydrogen atom, C3-C8- cycloalkyl, C1-C4- alkyl and (CH2)m- phenyl where m means a whole number 0-8; x means a whole number 1-8; n means a whole number 0-8; z is taken among a group including phenyl, heterocycle, cycloalkyl and naphthalene; M is taken among a group including hydrogen atom, C1-C4--alkyl,
and
where each
is taken independently among a group including hydrogen atom, C3-C8- cycloalkyl, C1-C4- alkyl and (CH2)m-phenyl where m' means a whole number 0-8; n' means a whole number 0-8; x' means a whole number 1-8; Q means hydrogen atom or
alkyl and Z' is taken among a group including phenyl, heterocycle, cycloalkyl and where Z is substituted optionally with 1-3 substitutes that can be similar or different and taken among a group including D, E,
and
where each D is taken independently among a group including trifluoromethyl group, trifluoromethoxy-group and C1-C4- alkoxy-group; each E is taken independently from a group including Hal, OH and C1-C8- alkyl; Z'' is taken from a group including phenyl, cycloalkyl and naphthalene; each
means hydrogen atom; n'' means a whole number 0-8; x'' means a whole number 1- 8; and M' means hydrogen atom where Z' can be substituted optionally with groups D', E'; each D' is taken independently among a group including trifluoromethyl group, trifluoromethoxy-group and C1-C4-alkoxy- group; each E' is taken independently among a group including Hal, OH and C1-C8- alkyl; R3 and R4 are taken among a group including hydrogen atom, C1-C4-alkyl and (CH2)y- phenyl where y means a whole number 0-8 under condition that both R3 and R4 can not mean hydrogen atom; R5 means C1-C8--alkylene and R1 is taken among a group including cyclopentyl, cyclopentenyl and isopropyl group and their pharmaceutically acceptable salts, optical isomers and hydrates under condition that when R2 means a group
where n means 1 or above then R1 means isopropyl or cyclopentyl group; R6 means hydrogen atom and Z is substituted with 1-3 substitutes that can be similar or different and taken among a group including
and
where D, b,
, x'', n'', M' and Z'' mean the above-mentioned values. Invention relates to method of treatment of patient with proliferation disorders by prescription of compound of the formula (I), to method of prophylaxis of nerve cells apoptosis, methods of protection of nerve cells against apoptosis and their disruption induced by antitumor agents and to pharmaceutical composition. EFFECT: valuable medicinal properties of compounds. 138 cl, 1 tbl, 152 ex
Title | Year | Author | Number |
---|---|---|---|
PRODRUG 1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | 2003 |
|
RU2357962C2 |
6,9-DISUBSTITUTED 2-[TRANS-(4-AMINOCYCLOHEXYL)-AMINO]PURINES | 1999 |
|
RU2191777C2 |
CYCLOALKYLAMINE-SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | 2007 |
|
RU2468011C2 |
CYCLOALKYLAMINE-SUBSTITUTED ISOQUINOLONE DERIVATIVES | 2007 |
|
RU2457203C2 |
LANTIBIOTIC CARBOXYAMIDE DERIVATIVES WITH ENHANCED ANTIBACTERIAL ACTIVITY | 2008 |
|
RU2506272C2 |
IMIDAZOLE DERIVATIVES AS TAFIa INHIBITORS | 2005 |
|
RU2375356C2 |
ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYLAMINES AND THEIR USING AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2301797C2 |
NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2829459C1 |
ASPARTATE PROTEASE INHIBITORS | 2006 |
|
RU2424231C2 |
Authors
Dates
2003-03-10—Published
1999-02-18—Filed